JSH-23: Selective Small Molecule NF-κB Inhibitor for Inflammation Research

Executive Summary: JSH-23 (CAS 749886-87-1) is a well-characterized NF-κB inhibitor with an IC50 of 7.1 μM, functioning by impeding p65 nuclear translocation without altering IκB degradation (APExBIO product page). In LPS-stimulated RAW 264.7 macrophages, JSH-23 suppresses pro-inflammatory mediators (IL-6, IL-1β, COX-2, TNF-α) and chromatin condensation (dela Pena-Ponce et al., 2017). In vivo, JSH-23 lowers biomarkers of injury and inflammation in cisplatin-induced acute kidney injury models. The compound is insoluble in water but demonstrates high solubility in DMSO (≥24 mg/mL) and ethanol (≥17.1 mg/mL with sonication). JSH-23 enables precise dissection of NF-κB-driven signaling events for both cell-based and animal model studies.

Biological Rationale

The NF-κB pathway regulates the transcription of genes responsible for inflammation, immune responses, and cell survival. Aberrant NF-κB activation is implicated in chronic inflammatory diseases, cancer, and acute tissue injury. The p65 (RelA) subunit is a critical mediator of NF-κB transcriptional activity. Inhibiting nuclear translocation of p65 represents a strategy to modulate inflammatory gene expression precisely. JSH-23, also known as 4-methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine, specifically targets this nuclear import step, allowing researchers to interrogate NF-κB's role without off-target effects on upstream events such as IκB degradation. This action distinguishes JSH-23 from broad-spectrum NF-κB inhibitors, providing mechanistic specificity and reducing confounding effects in experimental systems (related article—this article updates the mechanistic context with recent in vivo benchmarks).

Mechanism of Action of JSH-23

JSH-23 inhibits NF-κB-mediated gene transcription by blocking the nuclear localization of the p65 subunit. The compound does not inhibit IκB degradation, thus preserving upstream NF-κB signaling fidelity. This selectivity is confirmed in cell models such as LPS-stimulated RAW 264.7 macrophages, where JSH-23 reduces DNA binding activity of p65 without altering IκB phosphorylation or degradation status (dela Pena-Ponce et al., 2017). The molecular weight is 240.34 Da, and its chemical formula is C16H20N2. JSH-23 exhibits high solubility in DMSO (≥24 mg/mL) and in ethanol (≥17.1 mg/mL with ultrasound), but is insoluble in water, supporting its use in standard laboratory solvents. Storage at -20°C is recommended for stability; solutions are not suitable for prolonged storage. The compound's structure enables efficient cell uptake and bioactivity in both in vitro and in vivo settings.

Evidence & Benchmarks

• JSH-23 inhibits NF-κB transcriptional activity in vitro with an IC50 of ~7.1 μM in cell-based assays (APExBIO).
• In LPS-stimulated RAW 264.7 macrophages, JSH-23 reduces expression of IL-6, IL-1β, COX-2, and TNF-α (dela Pena-Ponce et al., https://doi.org/10.1371/journal.pone.0183324).
• JSH-23 prevents apoptotic chromatin condensation in inflammation models (see comparative review—this article provides updated in vivo efficacy data).
• In cisplatin-induced acute kidney injury in male C57BL/6 mice, intraperitoneal JSH-23 reduces BUN, serum creatinine, NGAL, IL-1, IL-6, CXCL1, TNF-α, tubular necrosis scores, and MPO activity, demonstrating anti-inflammatory and organ-protective effects (APExBIO).
• JSH-23 does not affect IκB degradation, allowing for precise delineation between nuclear events and cytoplasmic NF-κB regulation (mechanistic spotlight—this article covers new application boundaries in vivo).
• In airway epithelial models of H. pylori infection, JSH-23 minimally impacts IL-8 synthesis, confirming pathway specificity and highlighting context-dependent efficacy (https://doi.org/10.1371/journal.pone.0183324).

Applications, Limits & Misconceptions

JSH-23 is widely used as a tool for dissecting NF-κB-driven transcriptional programs in models of inflammation, immunity, and tissue injury. It is suitable for both in vitro (cell culture) and in vivo (animal) studies, including acute kidney injury, cancer, and infection/inflammation models. The compound is particularly valuable where mechanistic specificity—blocking p65 nuclear import without upstream interference—is required.

For extended practical guidance and troubleshooting, see this internal article—the current page provides new evidence on solubility, stability, and in vivo performance parameters.

Common Pitfalls or Misconceptions

• JSH-23 does not inhibit IκB degradation; it is ineffective for experiments requiring upstream NF-κB pathway blockade (evidenced in airway models).
• It is insoluble in water; attempting aqueous formulations will result in precipitation and loss of activity.
• JSH-23 is not recommended for long-term solution storage; activity may decrease significantly if stored in solvent for extended periods.
• In specific cell models (e.g., H. pylori-infected airway epithelia), JSH-23 minimally suppresses IL-8 synthesis, indicating pathway specificity and context-dependent limitations (see original).
• Not suitable as a pan-NF-κB inhibitor; only inhibits p65 nuclear translocation-dependent gene expression.

Workflow Integration & Parameters

JSH-23 (SKU B1645) is supplied as a solid by APExBIO. For in vitro use, dissolve in DMSO to a stock concentration of up to 24 mg/mL. Alternatively, ethanol (≥17.1 mg/mL) can be used with ultrasonic assistance. Typical working concentrations for cell-based assays range from 1–20 μM, depending on cell type and endpoint. For in vivo studies, intraperitoneal administration is standard, with doses reported effective in cisplatin-induced acute kidney injury models. Always filter-sterilize solutions and use freshly prepared aliquots. Store powder at -20°C; avoid repeated freeze-thaw cycles. JSH-23 is compatible with most standard laboratory inflammation or NF-κB assay protocols. For comparative workflows and troubleshooting, see here.

Conclusion & Outlook

JSH-23 is a validated, highly selective small molecule NF-κB p65 nuclear translocation inhibitor, widely used in inflammation research for both in vitro and in vivo models. Its unique mechanism enables precise dissection of transcriptional regulation without confounding upstream effects. Data from APExBIO and independent peer-reviewed studies support its role as a key tool in translational and mechanistic research of NF-κB signaling. Future studies may expand its application in disease modeling and therapeutic discovery, with ongoing optimization of formulation and delivery protocols.

For product specifications, protocols, and purchase, visit the APExBIO JSH-23 (SKU B1645) page.